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Abstract
Background and Aims: Smoking affects the course of inflammatory bowel disease [IBD]. We aimed 
to study the impact of smoking on IBD-specific costs and health-related quality-of-life [HrQoL] 
among adults with Crohn’s disease [CD] and ulcerative colitis [UC].
Methods: A large cohort of IBD patients was prospectively followed during 1 year using 3-monthly 
questionnaires on smoking status, health resources, disease activity and HrQoL. Costs were 
calculated by multiplying used resources with corresponding unit prices. Healthcare costs, patient 
costs, productivity losses, disease course items and HrQoL were compared between smokers, 
never-smokers and ex-smokers, adjusted for potential confounders.
Results: In total, 3030 patients [1558 CD, 1054 UC, 418 IBD-unknown] were enrolled; 16% smoked at 
baseline. In CD, disease course was more severe among smokers. Smoking was associated with > 
30% higher annual societal costs in IBD (€7,905 [95% confidence interval €6,234 – €9,864] vs €6,017 
[€5,186 – €6,946] in never-smokers and €5,710 [€4,687 – €6,878] in ex-smokers, p = 0.06 and p = 0.04, 
respectively). In CD, smoking patients generated the highest societal costs, primarily driven by the use 
of anti-tumour necrosis factor compounds. In UC, societal costs of smoking patients were comparable 
to those of non-smokers. Societal costs of IBD patients who quitted smoking > 5 years before inclusion 
were lower than in patients who quitted within the past 5 years (€ 5,135 [95% CI €4,122 – €6,303] vs 
€9,342 [€6,010 – €12,788], p = 0.01). In both CD and UC, smoking was associated with a lower HrQoL.
Conclusions: Smoking is associated with higher societal costs and lower HrQoL in IBD patients. 
Smoking cessation may result in considerably lower societal costs.
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1. Introduction
Inflammatory bowel disease [IBD] is an intestinal disorder compris-
ing Crohn’s disease [CD] and ulcerative colitis [UC]. Over 1 million 
residents in the USA and 2.5 million in Europe are estimated to have 
IBD.1 The chronicity and the relapsing nature of the disease have a 
debilitating effect on the lives of patients, and entail a high economic 
burden to society.2–4
It has been well established that cigarette smoking is a major envi-
ronmental factor in the course of IBD. Whereas smoking exerts delete-
rious effects in CD, beneficial effects have been observed in UC.5–9 In 
CD, smoking is associated with flares, hospitalizations, surgical proce-
dures and increased use of immunosuppressive drugs, whereas in UC, 
smoking has been linked to a reduced corticosteroid utilization and 
a reduced risk for colectomy.10–16 Smoking might therefore not only 
influence health-related quality of life [HrQoL], but might also have 
opposing economic consequences, from both a healthcare perspective 
and a societal perspective. To our knowledge, no studies have been 
performed to estimate the economic impact of smoking in IBD.
The aims of this study were to examine the impact of smoking on 
IBD-related costs and on HrQoL in adult IBD patients, from health-
care and societal perspectives.
2. Materials and Methods
This study was carried out with the approval of the Medical Ethics 
Committee [MEC] of the University Medical Centre Utrecht.
2.1. Study design and study population
The COIN-study [Costs Of Inflammatory bowel disease in the 
Netherlands]2 is a large multicentre cohort study initiated in 2010, aim-
ing to assess direct and indirect IBD-related costs and HrQoL. Patients 
aged 18 years or older, attending the IBD units from seven university 
medical centres and seven general hospitals, were eligible for participa-
tion. The study design has been described previously in detail.2
2.2. Data collection
Participants were invited to fill in a web-based baseline questionnaire, 
followed by 3-monthly questionnaires. At baseline, demographic data, 
smoking status, employment status, previous disease course, HrQoL, 
disease activity scores and data on current fistulas, stomas and pouches 
were extracted, based on self-report by patients. Patients reported their 
IBD diagnosis at baseline. Patients were assigned to ‘IBD-unknown’ 
when they did not know their IBD subtype, or reported UC with ileal 
involvement or fistulas. IBD-unknown patients were included in the 
total IBD population but were not assigned to either the CD or UC 
group in the outcome data. Used resources, disease course items and 
HrQoL were collected during 1 year of follow-up.
2.3. Smoking status
Smoking status of all patients was categorized into ‘current smokers’, 
‘ex-smokers’ and ‘never smokers’. From the ex-smoking patients, the 
date of smoking cessation was obtained.
2.4. Outcome variables
Disease activity was determined by both the presence or absence of 
self-reported flares and using disease activity scores. For CD and 
UC, the shortened Crohn’s Disease Activity Index and the modified 
Truelove and Witts Severity Index were employed, respectively.17,18 
Flares were noted based on a single question [‘Do you currently have 
a flare of IBD?’].
Healthcare costs were obtained by multiplying units of self-
reported healthcare utilization by their corresponding prices [using 
Dutch reference prices for health economic studies when appropri-
ate] [Supplementary Table S1, available as Supplementary data at 
ECCO-JCC online].2,19–21 Healthcare costs consisted of medication 
use, hospital admissions, surgeries, diagnostic procedures and out-
patient clinic visits.
Patient costs included costs such as travel costs and over-the-
counter drug use [for example analgesics and vitamins].
Productivity losses were calculated employing the human capital 
approach, and consisted of self-reported sick leave [absenteeism] of 
patients and their caregivers from both paid and unpaid [voluntary] 
work due to IBD-related illness, multiplied by age-and sex-specific 
mean gross wage income.19,22
Total costs, also referred to as societal costs, were calculated by 
summing healthcare costs, patient costs and productivity losses. For 
the healthcare perspective only healthcare costs were included, and 
for the societal perspective all costs were included. The time horizon 
was 1 year. All costs were expressed in 2014 euros. Of note, the 2014 
exchange rate between euros and US dollars was 0.754, and 0.814 
when applying purchasing power parity [PPP] approach.23
Work, productivity, activity impairment, employment status 
[employed, fully or partially incapacitated] and the average number 
of working hours per week were collected at baseline. Furthermore, 
impairment of work and daily activities was measured by the Work 
Productivity and Activity Impairment Questionnaire [WPAI].24 
Apart from absenteeism, this questionnaire measures impairment 
Smoking is Associated with Higher Costs and Lower QoL in IBD 343
in work productivity [ie presenteeism], and impairment in ability 
to perform daily activities other than work [eg shopping, house-
work, child care, exercising and studying] in the preceding 7 days.
Health-related quality-of-life: to assess disease-specific HrQoL, 
we used the validated Dutch version of the IBD-Questionnaire 
[IBDQ]25 which consists of four domains, ie bowel, systemic, 
social and emotional symptoms. Generic HrQoL was measured by 
employing the EuroQol EQ-5D-3L instrument26 which consists of 
a descriptive system encompassing five dimensions: mobility, self-
care, usual activities, pain and depression/anxiety, with three levels 
of functioning [no, any or severe problems], and the EQ visual ana-
logue scale [VAS]. Health states were scored using the Dutch tariff27 
to obtain EQ-5D-3L summary indices [EQ indices] ranging from 0 
[representing death] to 1 [representing full health].
2.5. Statistical analysis
Analyses were performed for the total IBD population and CD and 
UC population separately. Variables of disease activity were com-
pared between smokers and never-smokers, and smokers and ex-
smokers, using chi-square analysis. Mean annual costs [societal and 
healthcare costs] were calculated by summing the 3-monthly costs 
of the first four follow-up questionnaires. Costs were presented with 
95% confidence intervals [CI], and estimated using non-parametric 
bootstrap sampling. In order to represent complete annual costs, 
patients with missing data for cost items during one or more peri-
ods of follow-up were not included in this analysis. We performed 
a sensitivity analysis using multiple imputation techniques28,29 to 
assess the impact of missing data during follow-up. Pooled results 
of five imputations were compared with the complete case analy-
sis data to audit similarity of presented results using Rubin’s rule.29 
Univariable and multivariable logistic regression analysis was used 
to identify predictors for high costs [defined as the 10% patients 
with the highest total costs]. Multivariable analysis was performed 
with co-variables with a p –value < 0.10 in the univariable anal-
ysis, retaining age and gender in the final selection. Subsequently, 
costs of smokers, never-smokers and ex-smokers were mutually 
compared using independent samples t tests. Differences between 
patients who quitted smoking within and more than 5 years prior 
to enrolment were further analysed employing the chi-square test 
or Mann-Whitney U test, when appropriate. A post hoc multivari-
able analysis was performed to study the impact of ‘number of years 
after smoking cessation’ on healthcare costs. Factors with a p-value 
< 0.10 in the univariable analysis, age, gender and disease duration 
were incorporated in the multivariable analysis. Percentages of work 
impairment measured with the WPAI questionnaire were compared 
between smokers, never-smokers and ex-smokers with chi-square 
analysis. Univariable and multivariable logistic regression analysis 
was used to identify predictors for a low HrQoL [defined as the 10% 
patients with the lowest HrQoL]. Subsequently, variables of HrQoL 
were compared between smokers, never-smokers and ex-smokers 
using nonparametric Mann-Whitney U tests and chi-square analysis 
when normally distributed; p-values < 0.05 were considered statisti-
cally significant. All statistical analyses were performed with SPSS 
version 21.0 [Armonk, NY].
3. Results
3.1. Study population
In total, 3030 [1558 CD, 1054 UC and 418 IBD-unknown] patients 
were enrolled. Of all patients, 16% smoked at baseline. Smoking was 
more common in CD patients than in UC patients [21.1% vs 9.0%, 
p < 0.01]. Characteristics of smoking, never-smoking and ex-smok-
ing CD and UC study participants are shown in Table 1. Main char-
acteristics of the total IBD population are shown in Supplementary 
Table S2, available as Supplementary data at ECCO-JCC online. 
Smoking CD patients were more often female, were lower educated 
and were less frequently employed than never-smoking counterparts. 
Current smoking UC patients were more often unemployed than 
never-smokers. Ex-smoking CD and UC patients quitted smoking a 
median of 10 years (interquartile range [IQR] 5 – 18) and 14 years 
[IQR 8 – 25]) before inclusion. The overall response rate after 1 year 
of follow-up was 60% in CD and 66% in UC patients. Complete 
data on costs items covering all four questionnaires were available 
for 1200 patients. The incidence of current smoking was slightly 
lower in these 1200 patients compared with all 3030 patients 
[14.1% vs 17.3%, p = 0.02].
3.2. Disease activity
CD: at baseline, current smokers more frequently had active disease 
and fistulas, and reported a higher median number of flares in the 
past than never-smoking CD patients [Table  1]. During 1  year of 
follow-up, current smokers persistently had higher disease activ-
ity scores than never-smokers (baseline: Short-CDAI: median 170 
[IQR 128  –  219] vs 142 [IQR 114  –  198], p  <  0.01) [Figure  1; 
Supplementary Table S3, available as Supplementary data at ECCO-
JCC online]. Adjusted for abdominal surgery in the past, gender and 
age, current smoking was associated with an increased risk for anti-
tumour necrosis factor [TNF] use at t = 3 months (adjusted odds 
ratio [OR] 1.41 [95% CI 1.00 – 2.00, p < 0.05).
UC: ex-smokers patients more frequently experienced flares than 
current smokers at baseline [20.4% vs 11.6%, p < 0.05], and both 
ex-and never-smokers more frequently used steroids than current 
smokers [p  =  0.02 and p  <  0.05, respectively] [Table  1]. Overall, 
disease activity scores did not differ between current smokers and 
never- or ex-smokers [Figure 1; Supplementary table S3, available as 
Supplementary data at ECCO-JCC online].
3.3. Costs of smoking
IBD: among all covariates, a flare at baseline was the strongest 
predictor for high societal costs in IBD (adjusted OR of 3.08 
[95% CI 1.79 – 5.31, p < 0.01]). Adjusted for demographic data 
[ie gender, age, employment status, education level] and disease-
specific parameters [flares and previous abdominal surgery], cur-
rent smoking [as compared with never smoking] was associated 
with high societal costs in the whole IBD population with an OR 
of 1.92 [95% CI 1.14 – 3.24, p = 0.02] [Table 2]. Further specified, 
mean annual societal costs were 31% higher in the smoking IBD 
population than in the never-smoking population (€7,905 [95% 
CI €6,234 – €9,864] vs €6,017 [€5,186 – €6,946] p = 0.06), and 
38% higher than in the ex-smoking population (€5,710 [€4,687 – 
€6,878], p  =  0.04) [Figure  2, Table  3]. Total costs in IBD were 
mainly driven by healthcare costs [76% of total costs]. Healthcare 
costs were 40% higher in smokers than in never smokers (€6,381 
[95% CI €5,063 – €7,829] vs €4,573 [€4,011 – €5,206], p = 0.01) 
and 53% higher than in ex-smokers (€4,163 [€3,422 – €4,914], 
p < 0.01). Of healthcare costs, 65% was caused by the use of anti-
TNF compounds in smokers, compared with 56% in never-smok-
ers and 55% in ex-smokers. Patient costs were higher in smoking 
IBD patients than in never-smokers and ex-smokers [p = 0.02 and 
p  =  0.03, respectively]. There was no difference in productivity 
losses between smokers, never-smokers and ex-smokers [Table S3]. 
In our sensitivity analysis, calculated annual costs [ie healthcare, 
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patient, societal] were comparable to multiple imputed data, 
except for productivity losses [Supplementary Table S4, available 
as Supplementary data at ECCO-JCC online].
CD: current smokers were found to incur higher societal costs 
than never-smokers in CD, although not statistically significantly 
so (€10,261 [95% CI €7,852  – €12,690] in smokers vs €8,823 
[€7,351 – €10,387] in never-smokers, p = 0.36; and €8,211 [€6,380 – 
€10,228] in ex-smokers, p = 0.20) [Table 3].
UC: smoking was not associated with societal higher costs (€ 
3,641 [€1,954 – €5,624] in smokers vs €3,325 [€2,656 – €4,006] 
in never-smokers, p  =  0.78; and €3,983 [€2,719 – €5,532] in ex-
smokers, p = 0.83) [Table 3].
3.4. Effects of smoking cessation
Annual societal costs of IBD patients who quitted smoking more 
than5 years before inclusion were lower than those of patients who 
Table 1. Baseline characteristics, a comparison between smokers, ex-smokers and never-smokers.
1. Current smokers 2. Never-smokers 3. Ex-smokers p-Value [1 vs 2] p-Value [1 vs 3]
Crohn’s disease n = 329 n = 781 n = 448
Male gender, n [%] 90 [27.4] 306 [39.2] 178 [39.7] < 0.01 < 0.01
Age: years, mean [SD] 46.4 [12.1] 44.9 [14.2] 50.9 [12.7] 0.10 < 0.01
Low education, n [%] 251 [76.3] 451 [57.7] 306 [68.3] < 0.01 0.02
Currently employed, n [%] 141 [57.3] 405 [73.1] 192 [58.7] < 0.01 0.74
Disease duration: years, median [IQR] 14.9 [7.0 – 24.8] 14.8 [7.0 – 25.8] 17.3 [9.8 – 26.0] 0.87 0.01
Disease localization, n [%] 0.10 0.123
 Colon 73 [22.2] 227 [29.1] 131 [29.2]
 Small intestine 74 [22.5] 145 [18.6] 87 [19.4]
 Both colon and small intestine 170 [51.7] 379 [48.5] 219 [48.9]
 Unknown 12 [3.6] 30 [3.8] 11 [2.5]
Flare, n [%] 63 [19.1] 98 [12.6] 67 [15.0] 0.004 0.122
Fistula, n [%] 62 [18.8] 96 [12.3] 62 [13.8] 0.004 0.060
Stoma or pouch, n [%] 53 [16.1] 101 [12.9] 58 [13.6] 0.162 0.332
Abdominal surgery in the past, n [%] 182 [55.3] 404 [51.7] 257 [57.4] 0.274 0.570
Number of flares in the past, median [IQR] 7 [3 – 20] 5 [2 – 10] 6 [3 – 15] < 0.001 0.120
Medication use, n [%]* 196 [74.5] 492 [73.5] 280 [75.1] 0.759 0.877
 5-ASA 62 [23.5] 150 [22.4] 95 [25.4] 0.727 0.580
 Steroids 33 [12.5] 55 [8.2] 46 [12.3] 0.044 0.940
 Anti-TNF 69 [26.1] 144 [21.5] 86 [23.0] 0.131 0.362
 Immunosuppressive drugs [AZA/6MP/MTX] 97 [36.7] 253 [37.8] 113 [30.2] 0.760 0.084
Ulcerative colitis n = 95 n = 603 n = 358
Male gender, n [%] 42 [44.2] 284 [47.1] 202 [56.4] 0.60 0.03
Age: years, mean [SD] 46.9 [11.7] 46.9 [13.6] 53.6 [12.0] 1.00 < 0.01
Low education, n [%] 58 [61.1] 333 [55.2] 224 [62.6] 0.29 0.79
Currently employed, n [%] 60 [73.2] 363 [82.9] 191 [79.9] 0.04 0.20
Disease duration: years, median [IQR] 13.9 [8.8 – 21.2] 12.8 [6.4 – 21.2] 12.4 [5.8 – 20.8] 0.29 0.15
Flare, n [%] 11 [11.6] 89 [14.8] 73 [20.4] 0.411 0.049
Stoma or pouch, n [%] 10 [10.5] 88 [14.6] 50 [14.0] 0.289 0.379
Abdominal surgery in the past, n [%] 17 [17.9] 104 [17.2] 74 [20.7] 0.877 0.548
Number of flares in the past, median [IQR] 5 [3 – 15] 6 [3 – 15] 6 [3 – 15] 0.541 0.268
Medication use, n [%]a 54 [73.0] 420 [79.2] 242 [78.1] 0.219 0.349
 5-ASA 44 [59.5] 352 [66.4] 200 [64.5] 0.444 0.417
 Steroids 1 [1.4] 40 [7.6] 29 [9.3] 0.047 0.021
 Anti-TNF 3 [4.1] 17 [3.2] 15 [4.8] 0.703 0.774
 Immunosuppressive drugs [AZA/6MP/MTX] 16 [21.6] 127 [24.0] 60 [19.4] 0.657 0.660
SD, standard deviation; IQR, interquartile range; ASA, aminosalicylic acid; AZA, azathioprine; 6MP, 6-mercaptopurine; MTX, methotrexate; TNF, tumour 
necrosis factor.
aAfter 3 months of follow-up.
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Figure 1. Comparison of disease activity scores of smokers, ex-smokers and non-smokers over one year of follow-up.
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quitted smoking within 5 years before inclusion (€5,135 [95% CI 
€4,122  – €6,303] vs €9,342 [€6,010  – €12,788], p  =  0.01). This 
applied to patients with either CD or UC, although not statistically 
significantly so for the latter group [p < 0.05 and p = 0.42, respec-
tively] [Supplementary Table S5, available as Supplementary data 
at ECCO-JCC online]. In CD patients who quitted smoking within 
Table 2. Multivariable analysis for 10% highest total costs in inflammatory bowel disease.
10% highest societal costs 10% highest healthcare costs
Characteristics Unadjusted OR  
[95% CI]




Adjusted OR  
[95% CI]
p-Value
Current smoking [vs never-smoking] 1.97 [1.19 – 3.25]* 1.92 [1.14 – 3.24] 0.02 1.80 [1.10 – 2.93]* 1.38 [0.76 – 2.52] 0.29
Ex-smoking [vs never-smoking] 1.26 [0.80 – 1.88] - - 0.84 [0.54 – 1.31] - -
Female gender [vs male gender] 1.44 [0.98 – 2.12]* 1.09 [0.66 – 1.82] 0.62 1.68 [1.14 – 2.49]* 1.39 [0.77 – 2.50] 0.27
Low education [vs high education] 1.04 [0.71 – 1.53] - - 1.08 [0.73– 1.59] - -
Age [per year] 0.97 [0.95 – 0.98]* 0.96 [0.94 – 0.98] < 0.01 0.97 [0.95 – 0.98]* 0.95 [0.93 – 0.98] < 0.01
Disease duration [per year] 0.98 [0.96 – 1.00]* 1.00 [0.98 – 1.03] 0.89 0.99 [0.97 – 1.00] - -
Flare at baseline [vs remission at baseline] 3.06 [2.01 –4.67]* 3.08 [1.79 – 5.31] < 0.01 2.79 [1.82 – 4.27]* 2.99 [1.63 – 5.49 < 0.01
Employed at baseline [vs unemployed at 
baseline]
0.73 [0.47 – 1.15] - - 0.52 [0.33 – 0.81]* 0.52 [0.29– 0.93] 0.08
Abdominal surgery in the past [vs no 
abdominal surgery in the past]
1.33 [0.91 – 1.96] - - 1.61 [1.10 – 2.36]* 1.63 [0.94 – 2.83] 0.08
OR, odds ratio; CI, confidence interval. 













































Mean annual costs of UC patients
Figure 2. Mean annual costs of smokers, never-smokers and ex-smokers, expressed in 2014 euros.
346 M. Severs et al.
5 years before inclusion, anti-TNF compounds were more frequently 
prescribed than in patients who quit smoking longer than 5 years 
previously [34.4% vs 19.1%, p  < 0.01] [Supplementary Table S6, 
available as Supplementary data at ECCO-JCC online]. The post-
hoc multivariable analysis revealed that an increasing number of 
years after smoking cessation was associated with a lower risk for 
high annual healthcare costs in ex-smoking IBD patients, adjusted 
for age, disease duration, gender and disease severity (adjusted OR 
0.95 [95% CI 0.91- 0.99] per year, p = 0.02) [Table 4].
3.5. Employment rates
CD: current smokers were less frequently employed than never-smokers 
[57.3% vs 73.1%, p < 0.01] [Table 1], and more frequently partially 
incapacitated than never-smoking patients [21.6% vs 11.8%, p < 0.01]. 
Of the working CD population, never-smokers worked on average 
1.8 h more per week than current smokers {32.7 (standard deviation 
[SD] 8.6) vs 30.9 (SD 9.5), p = 0.04}, whereas ex-smokers worked on 
average 2.3 h more than current smokers (33.2 [SD 9.8], p = 0.04).
UC: in UC, no differences were found in employment rates 
between smokers and never-smokers [Table 1]. However, smoking 
patients were more frequently partially incapacitated than never-
smoking patients [18.9% vs 7.5%, p  <  0.01], and ex-smoking 
patients [18.9% vs 8.9% p = 0.01]. Among the employed UC popu-
lation, average working hours in never-smokers, smokers and ex-
smokers were comparable (33.6 [SD 9.0] vs 33.1 [SD 9.9] and 32.7 
[SD 9.6], respectively, overall p = 0.56).
3.6. Work, productivity and activity impairment
Measured over the preceding 7  days on one occasion during fol-
low-up, CD patients who currently smoked had more often been 
absent from work due to IBD-related illness (9% [SD 24] vs 4.1% 
SD [14.7], p = 0.04) and reported higher IBD-related activity impair-
ment than never-smokers [Figure 3, Supplementary Table S7, avail-
able as Supplementary data at ECCO-JCC online]. Furthermore in 
CD, current smokers reported a higher presenteeism, work and activ-
ity impairment than ex-smokers. In UC, current smokers reported 
higher work and activity impairment compared with never-smokers 
(work impairment 20.1 [SD 28.6] vs 12.1 [SD 17.8], p = 0.04), and 
higher activity impairment than both never-smokers and ex-smokers 
[Figure 3, Supplementary Table S7].
Table 3. Costs of smokers, never-smokers and ex-smokers in 2014 euros*
Mean + 95% CI 1.Current smokers 2.Never-smokers 3.Ex-smokers p-Value[1 vs 2] p-Value[1 vs 3]
IBD n = 169 n = 638 n = 393
Healthcare costs 6,381 [5,063 – 7,829] 4,573 [4,011 – 5,206] 4,163 [3,422 – 4,914] 0.01 < 0.01
 Hospitalizations 1,119 [639– 1,653] 828 [613– 1,070] 798 [488 – 1,199] 0.31 0.36
 Surgeries 18 [0 – 41] 54 [27 – 87] 18 [4 – 34] 0.25 1.00
 Anti-TNF use 4,119 [3,074 – 5,215] 2,572 [2,088 – 3,056] 2,296 [1,737 – 2,860] 0.01 < 0.01
 Other medication use 455 [416 – 490] 547 [51 – 581] 509 [451 –509] 0.03 0.21
 Diagnostics 173 [126 – 222] 148 [128 – 169] 146 [120 – 177] 0.33 0.31
 Outpatient clinic visits 449 [366 – 547] 381 [333 – 437] 374 [328 – 429] 0.23 0.13
Patient costs 355 [222 – 564] 208 [179 – 243] 192 [157 – 231] 0.02 0.03
Productivity losses 1,169 [453 – 2,091] 1,236 [816 – 1,747] 1,356 [741 – 2,065] 0.90 0.75
Societal costs 7,905 [6,234 – 9,864] 6,017 [5,186 – 6,946] 5,710 [4,687 – 6,878] 0.06 0.04
Crohn’s disease n = 114 n = 309 n = 169
Healthcare costs 8,316 [6,402– 10,228] 6,870 [5,798 – 7,949] 6,840 [5,350 – 8,470] 0.19 0.24
 Hospitalizations 1,514 [827– 2,317] 1,161 [766 – 1,572] 1,557 [835 – 2,491] 0.43 0.94
 Surgeries 27 [3 – 59] 52 [19 – 89] 29 [2 – 61] 0.46 0.91
 Anti-TNF use 5,571 [4,155 – 6,995] 4,503 [3,687 – 5,404] 4,119 [2,987 – 5,321] 0.23 0.13
 Other medication use 470 [393 – 553] 461 [407 – 520] 441 [374 – 514] 0.87 0.61
 Diagnostics 179 [123 – 241] 169 [139 – 198] 180 [136 – 229] 0.77 0.97
 Outpatient clinic visits 494 [396 – 596] 474 [399 – 558] 483 [401 – 578] 0.81 0.89
Patient costs 292 [232 – 359] 232 [184 – 287] 229 [164 – 310] 0.21 0.26
Productivity losses 1,654 [675 – 2,794] 1,721 [951 – 2,585] 1,142 [519 – 1,937] 0.94 0.49
Societal costs 10,261 [7,852 – 12,690] 8,823 [7,351 – 10,387] 8,211 [6,380 – 10,228] 0.36 0.20
Ulcerative colitis n = 38 n = 260 n = 165
Healthcare costs 3,287 [1,644 – 5,143] 2,508 [2,000 – 3,007] 2,368 [1,673 – 3,180] 0.36 0.31
 Hospitalizations 438 [0 – 1,176] 534 [314 – 777] 301 [101 – 551] 0.80 0.64
 Surgeries 0 [0 – 0] 42 [2 – 92] 11 [0 – 33] 0.53 0.63
 Anti-TNF use 1,611 [234 – 3,221] 765 [365 – 1,167] 941 [389 – 1,591] 0.20 0.39
 Other medication use 595 [465 – 732] 757 [703 – 808] 735 [666 – 799] 0.04 0.08
 Diagnostics 199 [128 – 279] 124 [96 – 154] 109 [80 – 144] 0.10 0.02
 Outpatient clinic visits 418 [227 – 654] 261 [220 – 303] 264 [217 – 324] 0.04 0.06
Patient costs 176 [109 – 252] 175 [130 – 224] 149 [111 – 187] 0.97 0.57
Productivity losses 177 [0 – 497] 642 [347 – 950] 1,467 [587 – 2,568] 0.33 0.26
Societal costs 3,641 [1,954 – 5,624] 3,325 [2,656 – 4,006] 3,983 [2,719 – 5,532] 0.78 0.83
IBD-unknown n = 17 n = 69 n = 59
Healthcare costs 338 [167 – 496] 2,066 [1,133 – 3,158] 1,507 [776 – 2,438] 0.16 0.19
Patient costs 1,178 [83 – 3,264] 227 [142 – 317] 208 [144 – 287] 0.07 0.08
Productivity losses 135 [11 – 324] 1,300 [263 – 2,754] 1,659 [388 – 3,419] 0.46 0.40
Societal costs 1,639 [386 – 3,810] 3,591 [1,938 – 5,633] 3,374 [1,710 – 5,549] 0.38 0.41
CI, confidence interval; IBD, inflammatory bowel disease; TNF, tumour necrosis factor.
*In 2014, 1€ was equal to 0.754 US$, or 0.814 US$ when using data on purchasing power parity.23
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3.7. Health-related quality of,life
The HrQoL was lower in the smoking population than in either 
never-smokers or ex-smokers, which applied to both CD and UC, 
both measured using disease-related and generic instruments at base-
line and during follow-up.
3.7.1. Disease-related HrQoL
Adjusted for demographic data and disease severity, current smoking 
was associated with the 10% lowest IBDQ scores as compared with 
never smoking, with an OR of 1.54 [95% CI 0.93–2.56, p = 0.09] 
in CD, and 1.55 [0.88 – 2.72, p = 0.13] in UC [Supplementary Table 
S8, available as Supplementary data at ECCO-JCC online]. Further 
specified, median IBDQscores of the total population at baseline 
were 170 [IQR 145 – 191] in smokers, vs 185 [161 – 202] in never-
smokers [p < 0.01], and 179 [158 – 198] in ex-smokers [p < 0.01] 
[Figure 4; Supplementary Table S9, available as Supplementary data 
at ECCO-JCC online].
3.7.2. Generic HrQoL
Adjusted for demographic data and disease severity, current 
smoking was associated with the 10% lowest EQ-VAS scores 
as compared with never smoking with an OR of 2.18 [95% CI 
1.33 – 3.58, p < 0.01] in CD, and 2.04 [0.94 – 4.41, p = 0.07] in 
UC [Supplementary Table S10, available as Supplementary data at 
ECCO-JCC online]. Current smoking was independently associated 
with the 10% lowest EQ indices as compared with never smoking, 
as well [Supplementary Table S10]. Further specified, in CD patients 
smoking was associated with more problems in all five dimensions of 
the EQ-5D-3L and resulted in lower EQ indices and lower EQ-VAS 
scores [Figure  4; Supplementary Table S10]. In UC, smoking was 
associated with more problems in all but the anxiety/depression 
dimension, and resulted in lower EQ indices and EQ-VAS scores.
3.7.3. Ex-smokers
For both CD and UC patients, the HrQoL did not differ between 
patients who quitted smoking within and more than 5 years prior 
to inclusion, independent of the instruments used [Supplementary 
Table S11, available as Supplementary data at ECCO-JCC online].
4. Discussion
In this large, prospective multicentre cohort study of over 3000 
IBD patients, we found that smoking was associated with sub-
stantial higher annual IBD-related societal and healthcare costs, 
40








































































































Figure 3. Percentages of impairment in work productivity and daily activities because of IBD of smokers, neversmokers and ex-smokers.
Table 4. Multivariate analysis for the 10% highest costs in the ex-smoking IBD population.
10% highest annual societal costs 10% highest annual healthcare costs









Number of years after smoking ces-
sation [per year]
0.96 [0.93 – 0.99] 0.96 [0.91 – 1.00] 0.06 0.95 [0.92 – 0.99] 0.95 [0.91 – 0.99] 0.02
Female gender [vs male gender] 1.34 [0.71 – 2.65] 1.09 [0.53 – 2.23] 0.82 1.37 [0.71 – 2.65] 1.03 [0.50 – 2.11] 0.95
Low education [vs high education] 2.03 [0.94 – 4.41] 2.00 [0.90 – 4.46] 0.09 2.03 [0.94 – 4.41] 2.00 [0.90 – 4.49] 0.09
Age [per year] 0.97 [0.94 – 0.99] 0.98 [0.95 – 1.02] 0.35 0.96 [0.94 – 0.99] 0.98 [0.94 – 1.01] 0.20
Disease duration [per year] 0.99 [0.96 – 1.02] 1.01 [0.97 – 1.04] 0.69 1.00 [0.97 – 1.03] 1.02 [0.99 – 1.06] 0.17
Flare at baseline [vs remission at 
baseline]
3.18 [1.55 – 6.51] 3.19 [1.51 – 6.77] < 0.01 3.18 [1.55 – 6.51] 3.27 [1.53 – 6.99] < 0.01
Employed at baseline [vs unemployed 
at baseline]
0.76 [0.33 – 1.71] - - 0.56 [0.25 – 1.27] - -
Abdominal surgery in the past [vs no 
abdominal surgery in the past]
1.10 [0.60 – 2.18] - - 1.40 [0.72 – 2.73] - -
Factors with a p-value < 0.10 in the univariable analyses, age, gender and disease duration were incorporated in the multivariable analyses.
Purchasing power parity is used to avoid the effects of the different levels of prices within a group of countries at a point in time.
CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio.
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predominantly driven by a higher use of anti-TNF compounds. 
Moreover, we found that the annual societal costs of patients who 
quitted smoking within 5 years before inclusion were higher than 
the annual societal costs of those who quitted more than 5  years 
previously. In both CD and UC, smokers reported a lower HrQoL 
than never-smokers, measured by both generic and disease-specific 
instruments.
Although the impact of smoking has been found to represent a 
substantial burden on national health services from a public health 
perspective,30–33 the economic impact of smoking in IBD or other 
chronic inflammatory conditions has never been evaluated. In our 
study, annual IBD-related societal costs were 31% higher among 
smokers compared with patients who never smoked. This associa-
tion was found to be independent of demographic characteristics 
and disease severity. The majority of these societal costs were driven 
by healthcare costs. CD patients are more likely to smoke than UC 
patients,34 and smoking has a well-established negative effect on the 
course of CD.5–7 The economic impact of smoking in IBD was there-
fore mainly determined by a higher consumption of healthcare in 
smoking CD patients. Specifically, we observed a higher prescription 
rate of anti-TNF compounds in smoking CD patients. We expected 
the societal costs of non-smoking UC patients to be higher than 
Figure 4. The Health-related quality of life of smoking, never-smoking and ex-smoking IBD patientsI. EQ-5D indices and EQ-VAS of ex-smokers can be found in 
table s.11. Scores ranged between those of smokers and never-smokers.
Smoking is Associated with Higher Costs and Lower QoL in IBD 349
those of current smokers. However, costs did not differ significantly 
between these groups. Therefore, the presented societal costs of IBD 
patients represent the total economic impact of smoking among 
the whole IBD population, including CD, UC and IBD-unclassified 
patients. The incidence of smoking among the 1200 patients of 
whom annual costs were analysed, was slightly lower compared 
with the smoking incidence of the total initial patient population 
[n  = 3030]. Since smoking was associated with higher costs, both 
healthcare and total costs may have been underestimated. However, 
a cost comparison with multiple imputed data showed no differences 
in cost outcomes.
Anti-TNF compounds are the main driver for increased health-
care costs in smokers. The most obvious explanation would be that 
this is the result of a ‘smoking-increased disease severity-anti-TNF 
sequence’. Since smoking is one of the established risk factors for 
rapid progression and disability in CD,5–7 it is also conceivable that 
treating physicians prescribe anti-TNF compounds in these patients 
in the context of progressive therapeutic decision making, irrespec-
tive of disease severity.
CD patients who quit smoking more than 5 years before inclu-
sion had substantially lower societal costs than those who quit more 
recently [p < 0.05]. This was mainly due to a lower use of anti-TNF 
compounds [p < 0.01]. In the multivariate analysis, we observed that 
the number of years after smoking cessation was significantly associ-
ated with a reduced risk for high costs, adjusted for disease duration. 
These results suggest that the negative effects of smoking on the dis-
ease course of CD diminish over time following smoking cessation.35 
This association may be [partially] caused by increased anti-TNF 
prescription rates over the past few years as well, as observed in our 
and other cohorts.36–38 In UC patients, costs of patients who quit 
smoking longer ago were also lower, but in these patients this was 
mainly caused by lower productivity losses. The lack of statistical 
significance in these patients can probably be attributed to a type 
II error. Obviously, we cannot infer a causal relationship between 
smoking and costs based on our results, because of the possibility 
of residual confounding. Smoking behaviour may be a proxy for an 
unhealthy lifestyle, such as a poor diet or a lack of physical activity. 
However, the finding that annual societal costs were considerably 
lower in patients who quit smoking longer ago provided additional 
support for causality. Recently, an economic evaluation for funding 
a smoking cessation programme for CD patients, using a Markov 
model, was published. 39 The perspective was the publicly funded 
healthcare system. All strategies [ie counselling, nicotine replacement 
therapy, nicotine replacement therapy + counselling, and Varenicline] 
were dominant [cost saving] over a strategy with no programme. The 
economic consequences of smoking in CD, as presented in our study, 
underscore this need for smoking cessation programmes. In clinical 
practice, a successful smoking cessation programme should include 
a multifaceted approach, aimed to raise awareness, educate, manage 
physical addiction and focus on the social context of smoking.40
Counterintuitively, productivity losses appeared to be slightly, 
but not statistically significantly, higher in ex-smokers and never-
smokers than in current smokers. These outcomes might have 
resulted from the fact that productivity losses were calculated by a 
formula including gender, age, number of absent days and number 
of hours worked per day. In this formula, higher salary rates were 
applied for increasing age and for men compared with women.22 
In our study, smoking participants were more often unemployed or 
partially incapacitated, worked fewer hours per week, were more 
often female and were younger. We speculate that this imbalance 
explains the slightly lower productivity losses found in smoking IBD 
patients. Since work and activity impairment was measured with 
IBD-specific tools, it is likely that productivity losses can be attrib-
uted to IBD-related causes.
Smoking was found to be a strong predictor for lower disease-
specific and generic HrQoL scores, both in CD and in UC patients, 
even after correction for known influencing factors for HrQoL.41,42 
As expected, the effect of smoking on HrQoL was most pronounced 
in CD. Nonetheless, smoking was not independently associated with 
the lowest 10% of IBDQ scores in our study, although its detrimen-
tal effect on the course of disease in CD is well known.5–7 Here, 
disease activity could have served as a collider for lower HrQoL 
scores in smoking CD patients.43 The employment of several tools 
for assessment of HrQoL corroborated our conclusion that smoking 
worsened the HrQoL in both CD and UC patients.
The strengths of our study included: the size of our cohort, 
representing the whole IBD population as being derived from 
both academic and non-academic centres; the prospective nature 
of data collection; and the fact that all relevant costs [healthcare 
costs, patient costs and productivity losses] were taken into account. 
However, self-report as a method to calculate the incurred costs 
has to be considered a limitation of this study. Patients may under-
report or exaggerate their consumption of healthcare. We recently 
reported that self-reported healthcare utilization in IBD patients is 
highly concordant with administrative data, however.44 Therefore 
we expect the current data to reliably reflect consumption of health-
care. Furthermore, as smoking behaviour was only recorded at 
baseline, we were not able to make allowances for patients who 
started or quit smoking during follow-up. Since smoking behav-
iour has been shown to be rather constant over a relatively short 
period of time,22,45 and fluctuations in smoking behaviour are likely 
to be balanced by the large size of our cohort, outcomes will not 
have been meaningfully altered by this constraint. Although smok-
ing was associated with substantial higher costs in CD patients, the 
differences in societal costs did not reach a statistically significant 
p-value of < 0.05. It can be argued that these cost differences are 
clinically relevant, however. Because of the broad inclusion criteria 
in cohort studies, study populations are more heterogeneous com-
pared with randomized trials, which impacts on confidence intervals 
of the outcomes. Hence, the application of strict p-values in obser-
vational cohort studies can be questioned.46 Moreover, outcomes in 
CD were fairly consistent, since smoking was found to have negative 
effects on the disease course, societal costs, IBD-related quality of 
life, generic quality of life and work productivity. Also, smoking ces-
sation was accompanied by a drop in societal costs, consistent with 
lower consumption of health care.
In the interpretation of the economic impact of smoking in IBD, 
concerns may arise regarding the representativeness of calculated 
costs. For example, selection bias may have been introduced by 
the fact that not all patients who were invited to participate in the 
COIN-study responded.2 Our non-responder-study revealed no rel-
evant differences between responders and non-responders regarding 
demographic data and disease course variables, however.2 Second, 
the response rate in the COIN-study after 1 year of follow-up was 
60% in CD and 66% in UC patients,47 and complete cost data of all 
questionnaires during this 1 year period were available in 1200 of 
3030 initial patients. In a comparison between patients who com-
pleted all follow-up questionnaires in the COIN study and patients 
who were lost to follow-up, responders were older and had longer 
disease duration.47 Since older age was associated with lower costs 
in this cohort, total costs may have been underestimated. However, 
presented costs in our study were comparable to costs calculated 
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by multiple imputation, which made it unlikely that missing data 
in this cohort caused major underestimation or exaggeration of 
true incurred costs. As participants were derived from 14 differ-
ent hospitals, and the disease duration at inclusion of study par-
ticipants ranged widely from 9 months to 73 years, we believe that 
our results truly reflected societal costs in an average IBD popula-
tion. Even though healthcare costs differ to a large extent between 
countries, comparable impacts of smoking on healthcare costs in 
European countries and the USA may be anticipated. We opted for a 
time frame of 1 year because of the good clinical interpretability of 
annual costs. As the costs of smokers after 1 year of follow-up were 
already considerably higher than those of non-smokers, it is likely 
that the full economic impact of smoking, measured over a longer 
period of time, will be even more important.
Smoking induces a spectrum of negative health effects in the 
general population, and is known to have deleterious effects on 
the course of CD. In the present study, it is clearly demonstrated 
that smoking is associated with a lower HrQoL in both CD and 
UC patients. Most importantly, smoking entails a substantial eco-
nomic burden to the healthcare system, which necessitates an active 
approach to achieve smoking cessation.
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